PUER ("Previously Unrecognized Emerging Risks") Life Clinical Study

NCT ID: NCT05687578

Last Updated: 2024-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-27

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a minimal risk, prospective, non-randomized, multi-center population based observational study to establish a physical baseline profile for individual study subjects using various modalities (blood draws, non-invasive imaging, stool samples, saliva samples) and identify deviations through longitudinal monitoring that may develop over time and may be relevant to human health and healthy longevity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The two key elements of the PUER Research protocol include (1) molecular and laboratory profiling and (2) non-invasive imaging and wearables/ "quantified self" measurements. All elements are optional. Molecular assessments will be conducted using peripheral blood samples, and potentially urine, stool or saliva samples. Non-invasive imaging assessment will consist of magnetic resonance imaging (MRI) and computerized tomography (CT) scans, ultrasound, and x-ray. All imaging modalities are optional. Other functional assessments, including respiratory, cardiac and other functions, as well as self-quantifiable assessments via wearables, may also be conducted and are optional.

The study will result in longitudinal data collection to inform if any modalities employed here can inform of baseline deviations for individuals. Researchers at study sites will not be blinded to the data being collected during this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measurements Only

This is an observational study only using biospecimen and imaging-based measurements only

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or non-pregnant female; age 18 to 90
* Absence or presence of any medical history or any signs or symptoms of any disease
* Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at all visits

Exclusion Criteria

* Unwillingness or inability to participate in the study
* Unwillingness or inability to provide written Informed Consent Form
* WOCBP with positive pregnancy test at enrollment or at any visit
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Puer Research, LLC

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Szilard Voros, MD

Role: PRINCIPAL_INVESTIGATOR

Puer Life

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Puer Research, LLC

Atlanta, Georgia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Kim DS, Bennett JT, Crosslin DR, Ranchalis J, Jones KL, Rosenthal EA, Jarvik ER, Itsara A, Turner EH, Herman DS, Schleit J, Burt A, Jamal SM, Abrudan JL, Johnson AD, Conlin LK, Dulik MC, Santani A, Metterville DR, Kelly M, Foreman AK, Lee K, Taylor KD, Guo X, Crooks K, Kiedrowski LA, Raffel LJ, Gordon O, Machini K, Desnick RJ, Biesecker LG, Lubitz SA, Mulchandani S, Cooper GM, Joffe S, Richards CS, Yang Y, Rotter JI, Rich SS, O'Donnell CJ, Berg JS, Spinner NB, Evans JP, Fullerton SM, Leppig KA, Bennett RL, Bird T, Sybert VP, Grady WM, Tabor HK, Kim JH, Bamshad MJ, Wilfond B, Motulsky AG, Scott CR, Pritchard CC, Walsh TD, Burke W, Raskind WH, Byers P, Hisama FM, Rehm H, Nickerson DA, Jarvik GP. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res. 2015 Mar;25(3):305-15. doi: 10.1101/gr.183483.114. Epub 2015 Jan 30.

Reference Type BACKGROUND
PMID: 25637381 (View on PubMed)

Arnoldi E, Gebregziabher M, Schoepf UJ, Goldenberg R, Ramos-Duran L, Zwerner PL, Nikolaou K, Reiser MF, Costello P, Thilo C. Automated computer-aided stenosis detection at coronary CT angiography: initial experience. Eur Radiol. 2010 May;20(5):1160-7. doi: 10.1007/s00330-009-1644-7. Epub 2009 Nov 5.

Reference Type BACKGROUND
PMID: 19890640 (View on PubMed)

Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, Andersson AC, Lindstedt P, Stenvang J, Gullberg M, Fredriksson S. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014 Apr 22;9(4):e95192. doi: 10.1371/journal.pone.0095192. eCollection 2014.

Reference Type BACKGROUND
PMID: 24755770 (View on PubMed)

Bennuru S, Lustigman S, Abraham D, Nutman TB. Metabolite profiling of infection-associated metabolic markers of onchocerciasis. Mol Biochem Parasitol. 2017 Jul;215:58-69. doi: 10.1016/j.molbiopara.2017.01.008. Epub 2017 Feb 8.

Reference Type BACKGROUND
PMID: 28188804 (View on PubMed)

Bromberg Y. Building a genome analysis pipeline to predict disease risk and prevent disease. J Mol Biol. 2013 Nov 1;425(21):3993-4005. doi: 10.1016/j.jmb.2013.07.038. Epub 2013 Aug 5.

Reference Type BACKGROUND
PMID: 23928561 (View on PubMed)

Chong CA, Tomlinson G, Chodirker L, Figdor N, Uster M, Naglie G, Krahn MD. An unadjusted NNT was a moderately good predictor of health benefit. J Clin Epidemiol. 2006 Mar;59(3):224-33. doi: 10.1016/j.jclinepi.2005.08.005.

Reference Type BACKGROUND
PMID: 16488352 (View on PubMed)

Crick F. Central dogma of molecular biology. Nature. 1970 Aug 8;227(5258):561-3. doi: 10.1038/227561a0. No abstract available.

Reference Type BACKGROUND
PMID: 4913914 (View on PubMed)

David CEB, Lucas AMB, Cunha PLO, Viana YIP, Yoshinaga MY, Miyamoto S, Filho ABC, Varela ALN, Kowaltowski AJ, Facundo HT. Calorie restriction changes lipidomic profiles and maintains mitochondrial function and redox balance during isoproterenol-induced cardiac hypertrophy. J Physiol Biochem. 2022 Feb;78(1):283-294. doi: 10.1007/s13105-021-00863-4. Epub 2022 Jan 13.

Reference Type BACKGROUND
PMID: 35023023 (View on PubMed)

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993 Feb 15;71(5):393-400. doi: 10.1016/0002-9149(93)90438-i.

Reference Type BACKGROUND
PMID: 8430625 (View on PubMed)

Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, Kim DS; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project; Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet. 2013 Oct 3;93(4):631-40. doi: 10.1016/j.ajhg.2013.08.006. Epub 2013 Sep 19.

Reference Type BACKGROUND
PMID: 24055113 (View on PubMed)

Fest J, Vijfhuizen LS, Goeman JJ, Veth O, Joensuu A, Perola M, Mannisto S, Ness-Jensen E, Hveem K, Haller T, Tonisson N, Mikkel K, Metspalu A, van Duijn CM, Ikram A, Stricker BH, Ruiter R, van Eijck CHJ, van Ommen GB, 't Hoen PAC. Search for Early Pancreatic Cancer Blood Biomarkers in Five European Prospective Population Biobanks Using Metabolomics. Endocrinology. 2019 Jul 1;160(7):1731-1742. doi: 10.1210/en.2019-00165.

Reference Type BACKGROUND
PMID: 31125048 (View on PubMed)

Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, Williams SA. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. JAMA. 2016 Jun 21;315(23):2532-41. doi: 10.1001/jama.2016.5951.

Reference Type BACKGROUND
PMID: 27327800 (View on PubMed)

Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010 Dec 7;5(12):e15004. doi: 10.1371/journal.pone.0015004.

Reference Type BACKGROUND
PMID: 21165148 (View on PubMed)

Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med. 2003 Sep 4;349(10):996-8. doi: 10.1056/NEJMe038132. No abstract available.

Reference Type BACKGROUND
PMID: 12954750 (View on PubMed)

Han X, Aslanian A, Yates JR 3rd. Mass spectrometry for proteomics. Curr Opin Chem Biol. 2008 Oct;12(5):483-90. doi: 10.1016/j.cbpa.2008.07.024.

Reference Type BACKGROUND
PMID: 18718552 (View on PubMed)

Hayden EC. Technology: The $1,000 genome. Nature. 2014 Mar 20;507(7492):294-5. doi: 10.1038/507294a. No abstract available.

Reference Type BACKGROUND
PMID: 24646979 (View on PubMed)

Lemaitre G, Marti R, Freixenet J, Vilanova JC, Walker PM, Meriaudeau F. Computer-Aided Detection and diagnosis for prostate cancer based on mono and multi-parametric MRI: a review. Comput Biol Med. 2015 May;60:8-31. doi: 10.1016/j.compbiomed.2015.02.009. Epub 2015 Feb 20.

Reference Type BACKGROUND
PMID: 25747341 (View on PubMed)

Li J, Huang A, Yao J, Liu J, Van Uitert RL, Petrick N, Summers RM. Optimizing computer-aided colonic polyp detection for CT colonography by evolving the Pareto fronta. Med Phys. 2009 Jan;36(1):201-12. doi: 10.1118/1.3040177.

Reference Type BACKGROUND
PMID: 19235388 (View on PubMed)

Netto, G., & Kaul, K, e. (2019). Genomic Applications in Pathology. Springer International Publishing

Reference Type BACKGROUND

Onal S, Lai-Yuen S, Bao P, Weitzenfeld A, Hart S. Fully automated localization of multiple pelvic bone structures on MRI. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:3353-6. doi: 10.1109/EMBC.2014.6944341.

Reference Type BACKGROUND
PMID: 25570709 (View on PubMed)

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9.

Reference Type BACKGROUND
PMID: 7968073 (View on PubMed)

Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky A, Winn ME, Schork NJ, Topol EJ; PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med. 2010 Oct 5;153(7):425-34. doi: 10.7326/0003-4819-153-7-201010050-00005.

Reference Type BACKGROUND
PMID: 20921541 (View on PubMed)

Scaria V. Personal genomes to precision medicine. Mol Cytogenet. 2014 Jan 21;7(Suppl 1 Proceedings of the International Conference on Human):I28. doi: 10.1186/1755-8166-7-S1-I28. eCollection 2014. No abstract available.

Reference Type BACKGROUND
PMID: 24949091 (View on PubMed)

Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015 Apr 30;520(7549):609-11. doi: 10.1038/520609a. No abstract available.

Reference Type BACKGROUND
PMID: 25925459 (View on PubMed)

Uppot, R.N., Boas, G., & Flores, E. (2018). Current Developments in Artificial Intelligence and Diagnostic Imaging

Reference Type BACKGROUND

Yang Q, Li L, Zhang J, Shao G, Zhang C, Zheng B. Computer-aided diagnosis of breast DCE-MRI images using bilateral asymmetry of contrast enhancement between two breasts. J Digit Imaging. 2014 Feb;27(1):152-60. doi: 10.1007/s10278-013-9617-4.

Reference Type BACKGROUND
PMID: 24043592 (View on PubMed)

Yet I, Menni C, Shin SY, Mangino M, Soranzo N, Adamski J, Suhre K, Spector TD, Kastenmuller G, Bell JT. Genetic Influences on Metabolite Levels: A Comparison across Metabolomic Platforms. PLoS One. 2016 Apr 13;11(4):e0153672. doi: 10.1371/journal.pone.0153672. eCollection 2016.

Reference Type BACKGROUND
PMID: 27073872 (View on PubMed)

Zhu B, Liu JZ, Cauley SF, Rosen BR, Rosen MS. Image reconstruction by domain-transform manifold learning. Nature. 2018 Mar 21;555(7697):487-492. doi: 10.1038/nature25988.

Reference Type BACKGROUND
PMID: 29565357 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PLI001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Project CARE: CAncer Risk Evaluation
NCT07130487 RECRUITING NA